Harrow Inc (OQ:HROW)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 102 WOODMONT BLVD, SUITE 610
NASHVILLE TN 37215
Tel: N/A
Website: https://www.harrow.com
IR: See website
<
Key People
Mark L. Baum
Chairman of the Board, Chief Executive Officer
Andrew R. Boll
Chief Financial Officer, Corporate Secretary
John P. Saharek
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
Business Overview
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Financial Overview
For the fiscal year ended 31 December 2023, Harrow Inc revenues increased 47% to $130.2M. Net loss increased 73% to $24.4M. Revenues reflect Product Sales Net segment increase of 41% to $117.4M. Higher net loss reflects Selling, general and administrative increase of 35% to $66.2M (expense), Interest expense increase from $7.2M to $21.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$0.75.
Employees: 315 as of Mar 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $484.09M as of Dec 31, 2023
Annual revenue (TTM): $130.19M as of Dec 31, 2023
EBITDA (TTM): $12.42M as of Dec 31, 2023
Net annual income (TTM): -$24.41M as of Dec 31, 2023
Free cash flow (TTM): -$148.70M as of Dec 31, 2023
Net Debt Last Fiscal Year: $100.41M as of Dec 31, 2023
Shares outstanding: 35,362,642 as of Mar 18, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.